1. Home
  2. AIFA vs TOVX Comparison

AIFA vs TOVX Comparison

Compare AIFA & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIFA

All In FutureTech Alliance Inc. Common Stock

N/A

Current Price

$2.10

Market Cap

14.7M

ML Signal

N/A

TOVX

Theriva Biologics Inc.

HOLD

Current Price

$0.25

Market Cap

14.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIFA
TOVX
Founded
N/A
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.7M
14.7M
IPO Year
2017
2012

Fundamental Metrics

Financial Performance
Metric
AIFA
TOVX
Price
$2.10
$0.25
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
51.5K
12.1M
Earning Date
N/A
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
89.07
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.08
$0.16
52 Week High
$2.53
$0.86

Technical Indicators

Market Signals
Indicator
AIFA
TOVX
Relative Strength Index (RSI) 34.55 43.56
Support Level $2.16 $0.23
Resistance Level $2.53 $0.27
Average True Range (ATR) 0.19 0.02
MACD -0.02 0.00
Stochastic Oscillator 30.83 20.16

Price Performance

Historical Comparison
AIFA
TOVX

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.

Share on Social Networks: